PARP1 and diabetes mellitus: Consequently, PARP-1 inhibitors, such as nicotinamide and 3-aminobenzamide, have been used to treat STZ-induced diabetic rat models, leading to a significant reduction in angiostatin isoforms, a key regulator of angiogenesis [84,85].